SAMSUNG PHARM. Co., LTD. (001360.KS)
KRW 1603.0
(0.25%)
KRW 1603.0
(0.25%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 23.74 Billion KRW | -3.54% |
| 2022 | 24.61 Billion KRW | 165.24% |
| 2021 | 9.28 Billion KRW | -11.19% |
| 2020 | 10.45 Billion KRW | 11.19% |
| 2019 | 9.39 Billion KRW | 9.43% |
| 2018 | 8.58 Billion KRW | 69.02% |
| 2017 | 5.08 Billion KRW | -33.21% |
| 2016 | 7.6 Billion KRW | -32.49% |
| 2015 | 11.27 Billion KRW | 32.62% |
| 2014 | 8.49 Billion KRW | -51.15% |
| 2013 | 17.39 Billion KRW | -9.09% |
| 2012 | 19.13 Billion KRW | 6.64% |
| 2011 | 17.94 Billion KRW | 7.94% |
| 2010 | 16.62 Billion KRW | 13.7% |
| 2009 | 14.62 Billion KRW | 7.37% |
| 2008 | 13.61 Billion KRW | 2.99% |
| 2007 | 13.22 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 5.35 Billion KRW | 34.91% |
| 2024 Q2 | 5.42 Billion KRW | 1.36% |
| 2023 Q3 | 5.64 Billion KRW | -29.95% |
| 2023 Q4 | 3.96 Billion KRW | -29.77% |
| 2023 Q1 | 5.46 Billion KRW | -3.22% |
| 2023 FY | 23.74 Billion KRW | -3.54% |
| 2023 Q2 | 8.06 Billion KRW | 47.52% |
| 2022 FY | 24.61 Billion KRW | 165.24% |
| 2022 Q1 | 8.02 Billion KRW | 1455.53% |
| 2022 Q2 | 3.17 Billion KRW | -60.42% |
| 2022 Q3 | 7.77 Billion KRW | 144.87% |
| 2022 Q4 | 5.64 Billion KRW | -27.35% |
| 2021 Q3 | 501.04 Million KRW | -86.31% |
| 2021 Q1 | 4.6 Billion KRW | 84.0% |
| 2021 FY | 9.28 Billion KRW | -11.19% |
| 2021 Q2 | 3.65 Billion KRW | -20.52% |
| 2021 Q4 | 515.68 Million KRW | 2.92% |
| 2020 Q2 | 1.72 Billion KRW | -54.67% |
| 2020 Q4 | 2.5 Billion KRW | 4.12% |
| 2020 FY | 10.45 Billion KRW | 11.19% |
| 2020 Q1 | 3.81 Billion KRW | 0.0% |
| 2020 Q3 | 2.4 Billion KRW | 38.99% |
| 2019 Q2 | 2.27 Billion KRW | -20.51% |
| 2019 Q1 | 2.86 Billion KRW | 914.85% |
| 2019 FY | 9.39 Billion KRW | 9.43% |
| 2019 Q3 | 4.89 Billion KRW | 115.09% |
| 2018 Q4 | 281.94 Million KRW | -80.62% |
| 2018 Q2 | 3.78 Billion KRW | 23.08% |
| 2018 FY | 8.58 Billion KRW | 69.02% |
| 2018 Q1 | 3.07 Billion KRW | 1352.84% |
| 2018 Q3 | 1.45 Billion KRW | -61.51% |
| 2017 Q3 | 1.56 Billion KRW | -11.68% |
| 2017 Q2 | 1.77 Billion KRW | -10.69% |
| 2017 Q1 | 1.98 Billion KRW | 532.64% |
| 2017 FY | 5.08 Billion KRW | -33.21% |
| 2017 Q4 | -245.18 Million KRW | -115.65% |
| 2016 Q4 | -459.11 Million KRW | -123.68% |
| 2016 FY | 7.6 Billion KRW | -32.49% |
| 2016 Q3 | 1.93 Billion KRW | -29.59% |
| 2016 Q2 | 2.75 Billion KRW | -18.39% |
| 2016 Q1 | 3.37 Billion KRW | -25.63% |
| 2015 Q1 | 2.62 Billion KRW | 32.99% |
| 2015 Q2 | 2.29 Billion KRW | -12.36% |
| 2015 Q3 | 1.26 Billion KRW | -44.82% |
| 2015 Q4 | 4.53 Billion KRW | 257.86% |
| 2015 FY | 11.27 Billion KRW | 32.62% |
| 2014 Q4 | 1.97 Billion KRW | 160.58% |
| 2014 Q3 | 756.71 Million KRW | -76.68% |
| 2014 Q2 | 3.24 Billion KRW | 28.48% |
| 2014 Q1 | 2.52 Billion KRW | 1.21% |
| 2014 FY | 8.49 Billion KRW | -51.15% |
| 2013 Q2 | 5.67 Billion KRW | 2.55% |
| 2013 Q3 | 3.68 Billion KRW | -35.04% |
| 2013 Q4 | 2.49 Billion KRW | -32.35% |
| 2013 Q1 | 5.53 Billion KRW | -1.38% |
| 2013 FY | 17.39 Billion KRW | -9.09% |
| 2012 Q2 | 5.34 Billion KRW | 27.09% |
| 2012 Q1 | 4.2 Billion KRW | -6.6% |
| 2012 Q3 | 3.97 Billion KRW | -25.71% |
| 2012 Q4 | 5.61 Billion KRW | 41.38% |
| 2012 FY | 19.13 Billion KRW | 6.64% |
| 2011 FY | 17.94 Billion KRW | 7.94% |
| 2011 Q3 | 3.31 Billion KRW | -39.09% |
| 2011 Q4 | 4.5 Billion KRW | 35.89% |
| 2011 Q1 | 4.68 Billion KRW | 59.52% |
| 2011 Q2 | 5.44 Billion KRW | 16.1% |
| 2010 Q3 | 4.07 Billion KRW | -23.85% |
| 2010 FY | 16.62 Billion KRW | 13.7% |
| 2010 Q2 | 5.34 Billion KRW | 25.15% |
| 2010 Q1 | 4.27 Billion KRW | 0.94% |
| 2010 Q4 | 2.93 Billion KRW | -27.83% |
| 2009 Q2 | 3.05 Billion KRW | -25.01% |
| 2009 Q3 | 3.26 Billion KRW | 7.02% |
| 2009 Q1 | 4.07 Billion KRW | 18.57% |
| 2009 FY | 14.62 Billion KRW | 7.37% |
| 2009 Q4 | 4.23 Billion KRW | 29.53% |
| 2008 Q1 | 3.72 Billion KRW | -10.41% |
| 2008 Q2 | 3.13 Billion KRW | -15.64% |
| 2008 FY | 13.61 Billion KRW | 2.99% |
| 2008 Q3 | 3.32 Billion KRW | 5.93% |
| 2008 Q4 | 3.43 Billion KRW | 3.26% |
| 2007 Q3 | 2.53 Billion KRW | -25.74% |
| 2007 Q2 | 3.4 Billion KRW | 8.99% |
| 2007 Q4 | 4.15 Billion KRW | 64.06% |
| 2007 FY | 13.22 Billion KRW | 0.0% |
| 2007 Q1 | 3.12 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 48.937% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 93.478% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | 88.06% |
| HANDOK Inc. | 151.36 Billion KRW | 84.312% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | 64.675% |
| Yuhan Corporation | 564.5 Billion KRW | 95.793% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 92.63% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 97.159% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | 68.354% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 88.065% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | 41.581% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | 74.875% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | 83.141% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 48.937% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | 31.596% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | 69.087% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 297.143% |
| JW Holdings Corporation | 446.15 Billion KRW | 94.677% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 88.558% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 96.376% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 92.926% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 69.795% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | 68.437% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | 67.115% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | 87.081% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | 48.937% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 91.953% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 96.516% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 92.926% |
| Yuhan Corporation | 564.5 Billion KRW | 95.793% |
| Jeil Pharma Holdings Inc | 201.82 Billion KRW | 88.234% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | 66.525% |
| Suheung Co., Ltd. | 99.02 Billion KRW | 76.02% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 92.926% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | 83.723% |
| Korea United Pharm Inc. | 173.48 Billion KRW | 86.312% |
| CKD Bio Corp. | 5.01 Billion KRW | -373.965% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 90.659% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | 87.103% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | 75.799% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | 69.795% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 93.608% |
| Boryung Corporation | 333.26 Billion KRW | 92.875% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | 52.549% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | 88.065% |
| JW Lifescience Corporation | 51.32 Billion KRW | 53.732% |